Website
http://dataportal.arc.gov.au/NCGP/API/grants/LP0561810
Funding Status
Closed
Does something not look right? The information on this page has been harvested from data sources that may not be up to date. We continue to work with information providers to improve coverage and quality. To report an issue, use the Feedback Form.
Funded Activity Summary
Improving and manipulating the immune adjuvant properties of recombinant fowlpox vectors. Unbalanced immune responses may cause or worsen common and important diseases such as infections, allergies, cancers and autoimmunity. Interleukin-4 (IL-4) is the only immune active product or cytokine that safely skews an aberrant immune response to a healing type of response. Fowlpox viruses (FPV) provide safe and effective human vaccines. Engineering FPV to make both a relevant antigen and a cytokine is proprietary technology. With our commercial partner and using experimental mice, we will test the concept that FPV making a model antigen and IL-4 initiate and/or maintain beneficial Type 2 responses. A successful outcome will guide clinical FPV-based vaccine development for the treatment of important human and veterinary diseases.Funded Activity Details
Start Date: 12-2005
End Date: 06-2008
Funding Scheme: Linkage Projects
Funding Amount: $165,000.00
Funder: Australian Research Council
Research Topics
ANZSRC Field of Research (FoR)
Medical Biotechnology | Tumor Immunology | Immunology | Cellular Immunology
ANZSRC Socio-Economic Objective (SEO)
Immune system and allergy | Prevention—biologicals (e.g. vaccines) | Cancer and related disorders |
